Roche Diagnostics Corporation Confirm Anti-Cd45 (Lca) (Rp2/18) Pab

Roche Diagnostics Corporation confirm anti-cd45 (lca) (rp2/18) pab; this antibody is intended for in vitro diagnostic (ivd) use. ventana medical systems, inc. (ventana) confirm anti-cd45, lca (rp2/18) primary antibody is a mouse monoclonal antibody (igg1) directed against cd45. confirm anti-cd45, lca (rp2/18) may be used in immunocytochemical methods to aid in the identification of normal and abnormal cells of leukocytic lineage and as an aid in the diagnosis of anaplastic tumors. confirm anti-cd45, lca (rp2/18) specifically binds to antigens located on the membrane of leukocytes. staining is most consistent for lymphocytic cells with less consistent reaction in other leukocytes (macrophages/ histiocytes/myeloid cells). the epitope recognized by the antibody is lca-rb. confirm anti-cd45, lca (rp2/18) is intended for laboratory use to qualitatively stain leukocytes in sections of formalin fixed, paraffin embedded tissue on a ventana automated slide stainer. light microscopy is used to detect the staining of cell components. the clinical interpretation of any staining, or the absence of staining, must be complemented by morphological studies and evaluation of proper controls. evaluation must be made by a qualified pathologist within the context of the patients clinical history and other diagnostic tests. prescription only. - ROCHMSD (Additional S&H or Hazmat Fees May Apply)